Organisation paid for research Program year 2025 Source: CMS Open Payments

Birmingham Hematology Onc Assoc

Neither a doctor nor a teaching hospital

Research payments

$250,151

16 payments

Through program year 2025, Birmingham Hematology Onc Assoc is reported as receiving $250,151 in research payments, across 16 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $70,665 1
2024 Research $86,784 4
2023 Research $50,631 3
2022 Research $7,650 2
2021 Research $19,059 3
2020 Research $5,406 1
2019 Research $9,955 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca UK Limited $200,715 7 payments
  2. AstraZeneca Pharmaceuticals LP $49,436 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 $150,759 3 payments
  2. Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents $37,074 8 payments
  3. CAMBRIA1 A Phase III, OpenLabel,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant AZD9833,a Next Generation, Oral Selective Estrogen Receptor Degrader vs Standard Endocrine Therapy Aromatase Inhibitor or Tamoxifen in Patients with ER HER2 Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrin Based Therapy Without Disease Recurrence $32,529 1 payment
  4. urvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian) $15,038 2 payments
  5. A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY $14,750 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record